Ariad approved to sell leukemia drug again in the U.S.
The approval ends a spate of bad new for Ariad that began in late October, when the FDA announced an investigation into the problems with the drug, which is approved for treatment of patients with advanced chronic myeloid leukemia. The company has …
Read more on Boston Business Journal (blog)

Bayer bids .9B to buy cancer drug company Algeta
Seven months after the approval of its first drug, Norwegian drug company Algeta ASA, which has 20 employees Cambridge, has received a $ 2.9 billion acquisition offer from its partner on that drug, German drug giant Bayer. Algeta opened its … In May …
Read more on Boston Business Journal (blog)

PSivida shares rise as FDA says another trial not needed for Iluvien
Shares of pSivida Corp. soared this morning after the company said U.S. regulators no longer need additional meetings or trials before making a decision on approval of its treatment for the back-of-the-eye disease, diabetic macular edema. The decision …
Read more on Boston Business Journal (blog)